SNOA
NASDAQ · Pharmaceuticals
Sonoma Pharmaceuticals Inc
$1.14
-0.02 (-1.72%)
Financial Highlights (FY 2026)
Revenue
55.10M
Net Income
-13,331,805
Gross Margin
38.2%
Profit Margin
-24.2%
Rev Growth
+4.2%
D/E Ratio
0.05
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 38.2% | 38.2% | 35.0% | 35.0% |
| Operating Margin | -26.0% | -23.4% | 23.2% | 24.4% |
| Profit Margin | -24.2% | -23.0% | 25.4% | 21.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 55.10M | 52.88M | 1.82M | 1.63M |
| Gross Profit | 21.08M | 20.23M | 638.4K | 569.1K |
| Operating Income | -14,309,563 | -12,359,507 | 423.5K | 396.5K |
| Net Income | -13,331,805 | -11,514,994 | 463.1K | 348.9K |
| Gross Margin | 38.2% | 38.2% | 35.0% | 35.0% |
| Operating Margin | -26.0% | -23.4% | 23.2% | 24.4% |
| Profit Margin | -24.2% | -23.0% | 25.4% | 21.5% |
| Rev Growth | +4.2% | +4.2% | -7.1% | +16.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 130.8K | 130.8K | 821.0K | 810.3K |
| Total Equity | 2.62M | 2.62M | 2.76M | 3.02M |
| D/E Ratio | 0.05 | 0.05 | 0.30 | 0.27 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -13,774,970 | -12,558,753 | 609.2K | 511.6K |
| Free Cash Flow | — | — | 381.4K | 338.4K |